The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Rationale for combining ibrutinib with tisa-cel in MCL
Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, explains the rationale for combining ibrutinib with tisagenlecleucel (tisa-cel) in mantle cell lymphoma (MCL), highlighting how ibrutinib can improve T-cell function. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Honoraria, Research Funding; Novartis: Other: Travel support, Research Funding.
